Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SQZ-PBMC-HPV Monotherapy and Combination in HPV16+ Solid Tumors
NCT04084951Phase 1Completed
- Sponsor
- SQZ Biotechnologies
- Start
- Jan 2020
- Primary completion
- Feb 2023
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 3
01
Overview
Phase 1, open-label trial of SQZ-PBMC-HPV in solid tumor, anal cancer, rectal cancer and 5 more (11 arms), sponsored by SQZ Biotechnologies. Primary endpoints: Treatment-related adverse events, Dose-limiting toxicity up to 1 year and 6 more. Started Jan 2020; status: completed.
02
Drugs
SQZ-PBMC-HPV
03
Conditions
solid tumoranal cancerrectal cancerCervical Cancer (CC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04084951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04084951.